stoxline Quote Chart Rank Option Currency Glossary
  
Assertio Holdings, Inc. (ASRT)
0.5886  -0.006 (-0.99%)    04-22 16:00
Open: 0.591
High: 0.6052
Volume: 308,902
  
Pre. Close: 0.5945
Low: 0.5701
Market Cap: 56(M)
Technical analysis
2025-04-22 3:45:29 PM
Short term     
Mid term     
Targets 6-month :  0.8 1-year :  0.93
Resists First :  0.69 Second :  0.8
Pivot price 0.61
Supports First :  0.51 Second :  0.42
MAs MA(5) :  0.6 MA(20) :  0.64
MA(100) :  0.8 MA(250) :  1.01
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  34.2 D(3) :  34.9
RSI RSI(14): 35.4
52-week High :  1.79 Low :  0.51
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ASRT ] has closed above bottom band by 30.1%. Bollinger Bands are 8.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.63 - 0.63 0.63 - 0.63
Low: 0.58 - 0.59 0.59 - 0.59
Close: 0.59 - 0.6 0.6 - 0.6
Company Description

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Headline News

Thu, 20 Mar 2025
Assertio CEO Reveals Growth Strategy at Elite Investor Conference - Key Insights Coming March 25 - Stock Titan

Thu, 13 Mar 2025
Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2024 Earnings Call Transcript - Insider Monkey

Wed, 05 Mar 2025
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 - GlobeNewswire

Wed, 12 Feb 2025
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel - GlobeNewswire

Sun, 02 Feb 2025
Investors in Assertio Holdings (NASDAQ:ASRT) have unfortunately lost 87% over the last five years - Yahoo Finance

Wed, 29 Jan 2025
Assertio Holdings faces Nasdaq delisting over share price rule - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 96 (M)
Shares Float 86 (M)
Held by Insiders 2.7 (%)
Held by Institutions 29.6 (%)
Shares Short 5,400 (K)
Shares Short P.Month 5,490 (K)
Stock Financials
EPS -0.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.26
Profit Margin -17.3 %
Operating Margin -27.4 %
Return on Assets (ttm) -4.6 %
Return on Equity (ttm) -16.7 %
Qtrly Rev. Growth -2.5 %
Gross Profit (p.s.) 0.89
Sales Per Share 1.3
EBITDA (p.s.) 0.05
Qtrly Earnings Growth 0 %
Operating Cash Flow 26 (M)
Levered Free Cash Flow 33 (M)
Stock Valuations
PE Ratio -2.55
PEG Ratio 0
Price to Book value 0.46
Price to Sales 0.44
Price to Cash Flow 2.12
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android